drugset

drugset / Trial / NCT06892119

Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation

NCT06892119 ↗

Phase 1 Completed 6 enrolled Hospital Universitario Dr. Jose E. Gonzalez

RandomizedParallel-groupSingle-blindOther

Summary

Generic plerixafor use at reduced-dose for mobilization on HSCT transplant

Timeline

Start: 2019-12-09
Primary completion: 2020-11-30
Completion: 2020-11-30

Publications

Results Gutierrez-Aguirre CH, Alvarado-Navarro DM, Palomares-Leal A, Mejia-Jaramillo G, Salazar-Riojas R, Leon AG, Colunga-Pedraza PR, Sotomayor-Duque G, Jaime-Perez JC, Cantu-Rodriguez OG, Del Carmen Tarin-Arzaga L, Flores-Jimenez JA, Gomez-Almaguer D. Reduced-dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study. Transfusion. 2019 Dec;59(12):3721-3726. doi: 10.1111/trf.15547. Epub 2019 Oct 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Celrixafor	Unknown	0.12 ug/kg	—

Indications